US64125C1099
© PR Newswire
09.12.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Host R&D Day on December 16
News Preview
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego....
Themefolio
Profiler
Peergroup
© PR Newswire
20.11.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
News Preview
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments
Review presents distinctive profile of INGREZZA, including selective VMAT2 targeting, simplified dosing w...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
News Preview
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
28.10.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
News Preview
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth
INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth
CRENES...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
17.10.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
News Preview
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms
90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary Movement S...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
News Preview
Conference Call and Webcast Scheduled for Tuesday, October 28
SAN DIEGO, Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
News Preview
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceuti...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
News Preview
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity
Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders®
SAN DIEGO, Oct. 6, 2...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
News Preview
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes.Post-hoc analysis from KINECT-PRO demonstrated substantial symptomatic remission rates at Week 24, even earlier than previous studies have reported.Patients who achieved sympto...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
News Preview
SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-10...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
News Preview
Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster AwardsSAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in ad...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
News Preview
SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September.
Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
30.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Reports Second Quarter 2025 Financial Results
News Preview
Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth
INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion
CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollm...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
News Preview
Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia
SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocri...
Themefolio
Profiler
Peergroup
© PR Newswire
15.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025
News Preview
Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journeyReal-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies...
Themefolio
Profiler
Peergroup
© PR Newswire
14.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
News Preview
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatmentSAN DIEGO...
Themefolio
Profiler
Peergroup
© PR Newswire
14.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
News Preview
One-year data from CAHtalyst™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasiaResults build upon previously reported one-year data from CAHtalyst™ Pediatric studySAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
News Preview
Conference Call and Webcast Scheduled for Wednesday, July 30
SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
News Preview
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
News Preview
Patient-reported analyses demonstrated greater reduction in both cognitive and motor-related disease burden for INGREZZA compared with placeboFindings to be presented at the 2025 Advanced Therapeutics in Movement & Related Disorders (ATMRD) CongressSAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today anno...
Themefolio
Profiler
Peergroup
© PR Newswire
20.06.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
News Preview
Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at the 2025 American Association of Nurse Practitioners (AANP) National Conference SAN DIEGO, June 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today ann...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
News Preview
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-...
Themefolio
Profiler
Peergroup
© PR Newswire
02.06.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
News Preview
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scalesPatients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional fu...
Themefolio
Profiler
Peergroup
© PR Newswire
28.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
News Preview
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-11175...
Themefolio
Profiler
Peergroup
© PR Newswire
16.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst™ Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
News Preview
One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtaly...
Themefolio
Profiler
Peergroup
© PR Newswire
16.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
News Preview
Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life MeasuresFindings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research ConferenceSAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced t...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY™ (crinecerfont)
News Preview
90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid ReductionObserved Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose ReductionsFindings Presented at the 2025 American Association of Clinical...
Themefolio
Profiler
Peergroup
© PR Newswire
14.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
News Preview
Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Na...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
News Preview
- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose
- Findings to be Presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology
SAN DIEGO, May 8, 2025 /PRNewswire/ -- Neurocri...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
News Preview
SAN DIEGO, May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in May.
Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
News Preview
New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatmentSAN DIEGO, May 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
News Preview
INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion
CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms
Initiated Phase 3 Registrational Programs for Osavampator in Major Depress...
Themefolio
Profiler
Peergroup
© PR Newswire
05.05.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
News Preview
-- Majority of individuals polled reported tardive dyskinesia negatively impacts their day-to-day ability to function, including individuals living with mild or moderate uncontrolled movements1
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the release of findings from a new survey conducted by...
Themefolio
Profiler
Peergroup
© PR Newswire
30.04.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
News Preview
SAN DIEGO, April 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's investigational oral muscarinic M4 selective orthosteric agonist, as a potential treatment for schizophrenia. Posit...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
News Preview
Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern
SAN DIEGO, April 24, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a post-hoc analysis from two 48-week studi...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
News Preview
Conference Call and Webcast Scheduled for Monday, May 5
SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
04.04.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
News Preview
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Med...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
News Preview
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six MonthsFindings Presented at the Academy of Managed Care Pharmacy 2025 Annual MeetingSAN DIEGO, March 31, 2025 /PRNewswire/ -- N...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
News Preview
Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric DisorderFindings Presented at the 2025 Psychiatry Update ConferenceSAN DIEGO, March 20, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 stu...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
News Preview
Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease ChoreaFindings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider SymposiumSAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD s...
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
News Preview
SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer Eiry Roberts will present at the conference....
Themefolio
Profiler
Peergroup
© PR Newswire
05.03.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
News Preview
SAN DIEGO, March 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
News Preview
SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line data from a Phase 4 study, KINECT-PRO™, demonstrating clinically meaningful and sustained effects of INGREZZA® (valbenazine) capsules on the physical, social and emotional impacts experienced by patients living with tardive dyskinesia (TD...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
News Preview
SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March.
Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chi...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
News Preview
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to t...
Themefolio
Profiler
Peergroup
© PR Newswire
06.02.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
News Preview
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively
INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion
CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with C...
Themefolio
Profiler
Peergroup
© PR Newswire
30.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
News Preview
Conference Call and Webcast Scheduled for Thursday, February 6
SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 6, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
News Preview
SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
News Preview
- Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator
- Takeda Reacquires Rights to Osavampator in Japan
SAN DIEGO, Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement w...
Themefolio
Profiler
Peergroup
© PR Newswire
23.01.2025
NBIX
LISTED
NASDAQ
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
News Preview
SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the continued transformation of Neurocrine's Chemistry, Manufacturing and Controls organization to...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
News Preview
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM), sponsored by the company. The supplement, titled "Challenges and Opportunities in the Management of...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
News Preview
Narrative Review Assesses Current Treatment Challenges and the Evolving Classic Congenital Adrenal Hyperplasia (CAH) Therapeutic LandscapeNon-Glucocorticoid (GC) Mechanisms for Treatment of CAH Could Enable Control of Excess ACTH and Androgens Without the Need for High-Dose GCs, Reducing Related Complications Over a LifetimeSAN DIEGO, Jan. 8, 202...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m. Pacific Time on Monday January 13, 2025 in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference....
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
News Preview
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S.CAH-trained pharmacists are available 24/7 to support patients with prescriptions exclusively through PANTHERx Rare, a specialty pharmacyNeurocrine Access Support is available to provide free, comprehensive access and...
Themefolio
Profiler
Peergroup
© PR Newswire
14.12.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
News Preview
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH
CRENESSITY is expected to be commercially avai...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Participate at Investor Conferences in December
News Preview
The 7th Annual Evercore HealthCONx Conference on December 3
Citi's 2024 Global Healthcare Conference on December 4
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in December. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Vi...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
News Preview
Data Support Positive Impact of INGREZZA in People With Huntington's Disease ChoreaFindings Presented at the 2024 Annual Meeting of the Huntington Study GroupSAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented subgroup analyses and data from the KINECT®-HD study showing the impact of INGREZZA® (valb...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences to Participate at Investor Conferences in November
News Preview
2024 UBS Global Healthcare Conference on November 12
Stifel 2024 Healthcare Conference on November 18
Jefferies London Healthcare Conference on November 19
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November....
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
News Preview
Findings Presented at the 2024 Psych Congress Include Data From More Than 300 PatientsSAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA® (valbenazine) capsules. These data showed significant improvements in func...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
News Preview
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of participants at Week 48 with once-daily INGREZZA® (valbenazine) capsules treatment. This research, "Remission of Tardive Dyskinesia in Patients Receiving...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
